Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer

PD-L1 expression is elevated in various human cancers, including colorectal cancer. High levels of PD-L1 expressed on tumor epithelial cells are one of the potential mechanisms by which tumor cells become resistant to immune attack. However, PD-L1 regulation in tumor cells is not fully understood. Here we demonstrate that mutations in the adenomatous polyposis coli (APC) gene lead to colonic epithelial cell resistance to CD8(+) T cell cytotoxicity by induction of PD-L1 expression. Mechanistically, this occurs as a result of the beta-catenin/TCF4 complex binding to the PD-L1 promoter, leading to increased transcription. Our findings not only reveal a novel mechanism by which APC mutations induce tumor immune evasion via an immune checkpoint pathway but also pave the way for developing beta-catenin or TCF4 inhibitors as possible new options for immune checkpoint inhibition.

Automated summary

Mutations in the APC gene lead to resistance of colonic epithelial cells to CD8(+) T cell cytotoxicity by inducing PD-L1 expression. This is mediated by the beta-catenin/TCF4 complex binding to the PD-L1 promoter, resulting in increased transcription. These findings suggest a potential new approach for immune checkpoint inhibition by targeting beta-catenin or TCF4.